| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.032 | 0.6 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.6 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.6 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.6 |